[{"orgOrder":0,"company":"CD (Suzhou) Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"CD-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CD (Suzhou) Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CD (Suzhou) Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"CD (Suzhou) Biopharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by CD (Suzhou) Biopharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : CD-001 is built on its BsFP platform. This potential therapy, designed to target PD-1 positive CD8+ T cells, aims to address unmet medical needs in oncology and viral infections.

                          Brand Name : CD-001

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 20, 2024

                          Lead Product(s) : CD-001

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank